Pacira BioSciences
PCRX
233 hedge funds and large institutions have $941M invested in Pacira BioSciences in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 78 increasing their positions, 79 reducing their positions, and 40 closing their positions.
696% more call options, than puts
Call options by funds: $19.8M | Put options by funds: $2.49M
22% more capital invested
Capital invested by funds: $772M → $941M (+$168M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 79
3% less funds holding
Funds holding: 239 → 233 (-6)
3.03% less ownership
Funds ownership: 111.16% → 108.12% (-3%)
10% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$20.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.9M |
| 3 |
Millennium Management
New York
|
+$15.4M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$7.98M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$29.8M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$12M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$8.87M |
| 4 |
Morgan Stanley
New York
|
-$8.62M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$8.47M |
PCRX Hedge Fund Activity: Q4 2024 in Review
233 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2024, worth a combined $941M — up 22% from $772M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of PCRX and 36 opened new positions — a net loss of 4 holders — while 79 trimmed existing stakes and 78 added.
The largest buyer was UBS Group, adding an estimated $20.8M. The largest seller was Pacer Advisors, cutting an estimated $29.8M.
- 233 institutional investors held Pacira BioSciences (PCRX) as of Q4 2024, down from 239 in Q3 2024.
- Funds reported $941M of Pacira BioSciences stock for Q4 2024, up 22% quarter-over-quarter.
- 36 funds opened new Pacira BioSciences positions in Q4 2024 and 40 closed out, a net change of -4 holders.
- The largest Pacira BioSciences buyer in Q4 2024 was UBS Group, an estimated $20.8M added.
- The largest Pacira BioSciences seller in Q4 2024 was Pacer Advisors, an estimated $29.8M sold.
Based on aggregated 13F filings for Q4 2024.